Legal Status Overview
Gray AreaNorth Dakota has no statute, administrative rule, or Board of Pharmacy bulletin that names peptides, "research chemicals," or research-use-only compounds as a distinct legal category. Instead, peptide-containing products are governed by North Dakota's general pharmacy practice law (North Dakota Century Code Title 43, Chapter 15) administered by the North Dakota State Board of Pharmacy, layered on top of the federal FDA framework that decides which drugs are approved, which bulk substances may be compounded under Sections 503A/503B of the Federal Food, Drug, and Cosmetic Act, and which require a prescription. In practice this means FDA-approved peptide drugs (e.g., prescription semaglutide, tirzepatide, or somatropin) are legal in North Dakota only when dispensed under a valid prescription through a licensed pharmacy, while unapproved peptides marketed as "not for human consumption" research chemicals (BPC-157, TB-500) sit in a regulatory gray zone with no dedicated North Dakota rule addressing them directly.
Key Points
- North Dakota Century Code Title 43, Chapter 15 establishes the North Dakota State Board of Pharmacy's authority over pharmacy practice and drug dispensing but does not create a separate category for peptides or research chemicals. [1]
- The North Dakota State Board of Pharmacy licenses and inspects pharmacies, including compounding pharmacies operating in the state, as part of its general regulatory authority rather than through any peptide-specific rule. [2]
- Under the federal 503A/503B compounding framework that North Dakota compounding pharmacies must follow, a bulk drug substance generally may only be compounded if it is a component of an FDA-approved drug, appears in an official USP/NF compendium, or is on an FDA-published bulks list, a bar that unapproved research peptides like BPC-157 do not meet. [3]
- FDA-approved GLP-1 peptide drugs such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) remain legal prescription medicines in North Dakota and must be dispensed through a licensed pharmacist consistent with state pharmacy law. [2]
- No North Dakota-specific statute, Board of Pharmacy bulletin, or attorney general guidance from the last two to three years was identified that separately addresses compounded GLP-1 drugs, BPC-157, TB-500, or other research peptides, so general compounding and FDA drug-approval law controls by default. [3]
- Personal possession or importation of unapproved research peptides for individual use in North Dakota is not addressed by any state-specific statute identified, so the general federal prohibition on introducing unapproved or misbranded drugs into interstate commerce is the only applicable framework and no North Dakota quantity or travel allowance exists. (No reliable source found for this point — flagged as unverified rather than stated as fact.)
Peptide-by-peptide status in North Dakota
| BPC-157 | BPC-157 is not an FDA-approved drug and, with no North Dakota statute naming it, cannot lawfully be compounded by a North Dakota pharmacy under the federal 503A criteria that require a bulk substance to be FDA-approved, compendium-listed, or on an FDA bulks list. [3] |
|---|---|
| Semaglutide / Tirzepatide (GLP-1 class) | Brand-name, FDA-approved semaglutide and tirzepatide products are legal prescription-only medicines in North Dakota and must be dispensed by a pharmacy licensed under the North Dakota State Board of Pharmacy. [2] |
| TB-500 | No North Dakota-specific or confirmed federal source was found directly naming TB-500, but as an unapproved peptide it would fall under the same general 503A compounding limitation described for BPC-157 rather than any dedicated North Dakota rule. [3] |
| Human Growth Hormone (HGH / Somatropin) | Prescription human growth hormone (somatropin) is a legal medicine in North Dakota only when dispensed under a valid prescription through a pharmacy licensed by the North Dakota State Board of Pharmacy, consistent with the state's general pharmacy practice law. [2] |
Sources
Last researched: 2026-10-02
Frequently asked questions
Can I buy peptides in North Dakota without a prescription?
No: FDA-approved peptide drugs like prescription semaglutide, tirzepatide, or somatropin require a valid prescription dispensed through a North Dakota-licensed pharmacy, and unapproved research peptides such as BPC-157 are not lawfully sold for human use regardless of prescription status. [2]
Is BPC-157 legal to buy in North Dakota?
BPC-157 is not FDA-approved and has no North Dakota-specific rule permitting it, so it does not meet the federal criteria that would allow a North Dakota pharmacy to legally compound or sell it for human use. [3]
Can a North Dakota pharmacy legally compound semaglutide or tirzepatide?
A North Dakota compounding pharmacy may only compound these drugs within the limits of the federal 503A/503B framework, such as when a patient-specific prescription requires a customized formulation; routine copying of a commercially available, non-shortage FDA-approved product is generally not permitted. [3]
What are the penalties for selling illegal research peptides in North Dakota?
No North Dakota-specific peptide enforcement action or penalty statute was identified in this research; sellers would instead be exposed to the general federal prohibitions on distributing unapproved or misbranded drugs, since North Dakota has not enacted a peptide-specific penalty scheme.
Can a telehealth provider prescribe peptides to patients in North Dakota?
A telehealth provider licensed to prescribe in North Dakota can lawfully prescribe FDA-approved peptide medicines (such as semaglutide) under the state's normal prescribing and pharmacy-dispensing rules, but no North Dakota-specific telehealth rule was identified that separately authorizes prescribing unapproved research peptides. [2]